MIF and Alzheimer disease: If the anti-MIF antibody (clinicaltrial.gov identifier: NCT01765790) in phase I clinical trial turns out to be safe for humans, another clinical trial may be initiated to test its efficiency in AD patients with elevated MIF levels in CSF.